Instructional Course - Requires Course Pass, Additional Registration Required

Instructional Course

065IC - Prostate Cancer Focal Therapy: Is it the Right Time for Your Practice?

Monday, May 21
10:00 AM - 12:00 PM
Location: MCC WEST 2010

his course will focus on the controversial topic of focal therapy for prostate cancer. With the approval of high frequency ultrasound (HIFU) for localized prostate cancer, there will be renewed discussions about whether or not now is the time to learn and adopt focal therapy in routine clinical practice. This course will attempt to present the evidence for and against focal therapy in an evidence-based, bias-free manner.

We will review its indications, existing platforms, imaging approaches, energy sources and outcomes of currently published data on various modalities such as HIFU, Laser, Electrical, Nano particles and Cryo etc. We will also focus on who is a candidate, how to treat,full gland versus hemi gland versus targetd therapy, how to monitor, and when to declare failure and salvage. Technical topics will be outlined such as state-of-the-art imaging required, monitoring/biopsy techniques, and consequences of failure and need for salvage therapy. At the end of this course, participants should be able to independently judge whether or not focal therapy is a significant advance compared to existing active surveillance, radiation, and surgical treatments.

Learning Objectives:

John Warren Davis

MD Anderson Cancer Center

John W. Davis, MD, FACS is an associate professor of urology and director of the prostate cancer surgery program at MD Anderson Cancer Center, where he was appointed to the faculty in 2006. Previously, he was an assistant professor at Eastern Virginia Medical School. Recent leadership roles include committees with the AUA (Bylaws, History, Laparoscopic and Robotic Technology), president of the Society of Urological Robotic Surgeons, and Associate Editor for the British Journal of Urology International. He is the Online Content Editor for the AUA. He is a member of the South Central Section of the AUA and serves as the Historian. He is a graduate of the AUA leadership program in 2015.
Dr. Davis received his B.S. degree in biology (Cum Laude) from Davidson College, and M.D. from the University of Virginia. After urology residency at Eastern Virginia Medical School, he completed fellowships in the basic sciences as an American Foundation of Urologic Disease Fellow, as a clinical fellow in urologic oncology at MD Anderson Cancer Center, and in laparoscopic surgery at Charité Hospital, Berlin, Germany.

Presentation(s):

Send Email for John Davis

Peter A. Pinto

National Cancer Institute, National Institutes of Health

Presentation(s):

Send Email for Peter Pinto

Ardeshir R. Rastinehad

Icahn School of Medicine at Mount Sinai

Art Rastinehad, D.O. joined the faculty at Mount Sinai as Associate Professor of Radiology and Urology. He trained at the National Cancer Institute as an Interventional Urologic Oncologist and is the first urologist to be dual fellowship trained in Urologic Oncology and Interventional Radiology. He has expertise in a wide array of interventional radiological and surgical techniques, including image guided procedures, laparoscopic and robotic surgery.

Dr. Rastinehad’s prostate cancer team has now incorporated state-of-the-art imaging to help visualize suspicious areas in the prostate for cancer. Dr. Rastinehad has also authored and implemented clinical trials of new techniques in the diagnosis and treatment of localized prostate cancer. Most recently, he is the principle investigator for a Phase III clinical trial using MRI/Ultrasound fusion technology to improve prostate biopsy techniques. Using information from the prostate MRI, we can now target specific areas to better diagnose and quantify a patient’s prostate cancer. This was the first trial of this technology in the United States outside the National Institutes of Health. This new clinical approach is helping to lay a foundation for the evaluation of a new technique, Focal Therapy, which only treats the diseased portion of the prostate. As of May 216, Dr Rastinehad was the first in the world to perform a gold nano-particle directed ablation using an transperineal MR US Fusion guided focal therapy system.

For more information, please visit www.interventionalurology.com

Dr. Rastinehad’s research has been published in leading national and international medical journals including The Journal of Urology, Journal of Radiology, Urology, and The British Journal of Urology. He has also authored several book chapters. He has also served as the course director for the first international course on MR US fusion guided prostate biopsies sponsored by the American Urological Association.

Presentation(s):

Send Email for Ardeshir Rastinehad

Ashutosh K. Tewari

Icahn School of Medicine at Mount Sinai

Ashutosh (Ash) K. Tewari, MBBS, MCh, Chairman, Milton and Carroll Petrie Department of Urology, Mount Sinai Health System and Professor, Urology at the Icahn School of Medicine at Mount Sinai is a world-renowned urologist and prostate cancer specialist. As Director of the Department of Urology, he leads a multidisciplinary team committed to improving prostate cancer treatment, research and education. A pioneer of daVinci robotic surgery for prostate cancer, Dr. Tewari was part of the team that performed the first robotic radical prostatectomy in the United States and he has performed over 5,500 robotic radical prostatectomy surgeries to date. Importantly, he has refined the standard robotic surgical technique to improve cancer control and greatly decrease side effects, improving quality of life for his patients. At Mount Sinai, The Tewari Lab is working on unlocking the genomic causes of prostate cancer. Another goal of his research is to develop effective immunotherapy agents, personalized to a patient's own tumor and with increased ability to educate a patient's immune system to eliminate cancer. Dr. Tewari has been consecutively noted as a Castle Connolly and New York Magazine Top Doctor since 2006.

Presentation(s):

Send Email for Ashutosh Tewari


Assets

065IC - Prostate Cancer Focal Therapy: Is it the Right Time for Your Practice?



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Prostate Cancer Focal Therapy: Is it the Right Time for Your Practice?